Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

SEATTLE--(BUSINESS WIRE)--Feb. 13, 2017-- Gilead Sciences, Inc.(NASDAQ:GILD) today announced findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment. The study identified novel HIV-1 capsid inhibitors with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro. The data are being presented in an oral session (Session O-4) at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=2245714